Combination therapy with SGLT2i and GLP-1 RA reduced all-cause death (HR 0.43) and hospitalization (HR 0.87) versus SGLT2i monotherapy in patients with heart failure and type 2 diabetes.
Does combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists reduce all-cause death and hospitalization in patients with heart failure and type 2 diabetes compared to SGLT2 inhibitor monotherapy?
In patients with heart failure and type 2 diabetes, adding a GLP-1 RA to SGLT2i therapy is associated with significantly lower risks of all-cause mortality and hospitalization at 1 year compared to SGLT2i monotherapy.
Absolute Event Rate: 0% vs 0%
INTRODUCTION: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve cardiovascular outcomes in type 2 diabetes (T2D), and SGLT2i reduces events in heart failure (HF). However, the benefit of their combination in patients with both conditions remains unclear. This study assessed the risk of all-cause death and hospitalization with combination therapy versus SGLT2i monotherapy. RESEARCH DESIGN AND METHODS: This multicenter, retrospective, observational study used the TriNetX database between January 1, 2018, and December 31, 2021. We identified 928,981 patients aged ≥18 years with HF and T2D. Of these, 168,422 received an SGLT2i. The exposure group comprised patients who initiated a GLP-1 RA within 6 months of SGLT2i initiation, while the control group included those who did not receive a GLP-1 RA after SGLT2i initiation. The index date was defined as 6 months after SGLT2i. 25,989 patients received SGLT2i and GLP-1 RA and 54,619 received SGLT2i monotherapy. Following propensity score matching, each group comprised 23,240 patients. RESULTS: Over 1 year, the risk of all-cause death in patients who received SGLT2i and GLP-1 RA relative to those who received SGLT2i monotherapy was significantly lower (2.8% vs 6.3%, p<0.001; HR 0.43; 95% CI 0.39 to 0.48). Similarly, the risk of hospitalization in patients who received SGLT2i and GLP-1 RA was also lower (32.9% vs 36.4%, p<0.001; HR, 0.87; 95% CI 0.84 to 0.90). CONCLUSIONS: The risk of all-cause death and hospitalization in patients who received combination therapy with SGLT2i and GLP-1 RA relative to those who received SGLT2i monotherapy was significantly lower in patients with HF and T2D.
Kishimori et al. (Sat,) reported a other. Combination therapy with SGLT2i and GLP-1 RA reduced all-cause death (HR 0.43) and hospitalization (HR 0.87) versus SGLT2i monotherapy in patients with heart failure and type 2 diabetes.